Panobinostat, a pan-deacetylase inhibitor that depletes JAK2V617F levels and JAK/STAT signaling in MPN cells, reduced IL-6 level in plasma of PMF patients [39]. Here, IL6 is linked to myeloproliferative neoplasm.